Immunophage Biotech Co., Ltd (referred to as "Immunophage") achieved a significant milestone in 2021 by obtaining Investigational New Drug (IND) approvals for six indications in both the United States and China. These approvals were secured in August and December 2021, marking a remarkable achievement within six months since the company's establishment.
Among these six IND approvals, five were attributed to Immunophage's internally developed IPG1094 pipeline. IPG1094 is a small molecule inhibitor targeting macrophage migration inhibitory factor (MIF) for five disease indications: multiple myeloma, solid tumors, multiple sclerosis, systemic lupus erythematosus, and psoriasis. These clinical trials are being conducted in Australia, the United States, and China.
In addition to IPG1094, another promising candidate in Immunophage's rapidly advancing first-tier clinical pipeline is IPG7236. IPG7236 is a CCR8 antagonist, its potential in treating various solid tumors is being investigated, and it has obtained IND approvals from the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA). Clinical trials for IPG7236 are currently underway in China, Australia, and the United States.
Aside from the first-tier candidates IPG1094 and IPG7236, Immunophage has over ten additional programs in its pipeline, categorized as second-tier, third-tier, fourth-tier, and fifth-tier. All these innovative assets are first-in-class drugs developed independently by the company.
In an exclusive interview with VBDATA, Dr. Guohuang Fan, the founder of Immunophage Biopharmaceuticals, provided valuable insights into the company's development history, core products, competitive advantages, and future plans. The interview highlighted Immunophage Biopharmaceuticals' unwavering commitment to advancing healthcare and its strategic vision for continued growth and innovation.